Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 6.
Article
Hayes, AR;
Mak, IYF;
Evans, N;
Naik, R;
Crawford, A;
Khoo, B;
Grossman, AB;
... Meyer, T; + view all
(2021)
Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.
Neuroendocrinology
, 111
(9)
pp. 863-875.
10.1159/000511662.
|
|
Laskaratos, F-M;
Armeni, E;
Shah, H;
Megapanou, M;
Papantoniou, D;
Hayes, AR;
Navalkissoor, S;
... Toumpanakis, C; + view all
(2020)
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
Endocrine
, 67
pp. 233-242.
10.1007/s12020-019-02086-6.
|
 |
|
Manoharan, P;
Lamarca, A;
Navalkissoor, S;
Calero, J;
Chan, PS;
Julyan, P;
Sierra, M;
... Valle, J; + view all
(2020)
Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
ESMO Open
, 5
(2)
10.1136/esmoopen-2019-000650.
|
|
|
Nastos, K;
Cheung, VT;
Toumpanakis, C;
Navalkissoor, S;
Quigley, AM;
Caplin, M;
Khoo, B;
(2017)
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Journal of Surgical Oncology
, 115
(4)
pp. 425-434.
10.1002/jso.24553.
|
|
Navalkissoor, S;
Flux, G;
Bomanji, J;
(2017)
Molecular radiotheranostics for neuroendocrine tumours.
Clinical Medicine
, 17
(5)
pp. 462-468.
10.7861/clinmedicine.17-5-462.
|
|
Shekhda, Kalyan Mansukhbhai;
Armeni, Eleni;
Xu, Yiwang;
D’afflitto, Manfredi;
Hayes, Aimee;
Mandair, Dalvinder;
Yu, Dominic;
... Khoo, Bernard; + view all
(2025)
Peptide Receptor Radionuclide Therapy (PRRT) with 177 Ludotatate in Metastatic Phaeochromocytomas and
Paragangliomas – a single centre retrospective
analysis of experience at an ENETS centre of excellence.
Endocrine Oncology
10.1530/eo-25-0019.
(In press).
|
|
